{'fraction_non_alphanumeric': 0.024830699774266364, 'fraction_numerical': 0.011286681715575621, 'mean_word_length': 5.8307692307692305, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer

Oesophageal cancer carries a poor prognosis. The 5‐year survival rate following resection ranges from 10 to 35 per cent. Recent evidence suggests that the addition of non‐surgical treatments to surgery may improve resection rates, reduce the risk of recurrence and improve survival. This review examines the role of preoperative chemoradiotherapy (CRT) in oesophageal cancer.